Unjha Life Science Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 2 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth %
- Profit Growth -90.15%
- Ebitda -90.15%
- Net Worth -1.86%
- Total Assets %
About Unjha Life Science
Unjha Life Science Private Limited (ULSPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 December 2014 and has a history of Ten years and two months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Malav Shah, Gatha Shah, and Arpita Shah serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24100GJ2014PTC081558
- Company No.
081558
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Dec 2014
- Date of AGM
20 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Unjha Life Science?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Malav Shah  | Director | 16-Dec-2014 | Current |
| Gatha Shah | Director | 16-Dec-2014 | Current |
| Arpita Shah | Director | 16-Dec-2014 | Current |
Financial Performance of Unjha Life Science.
Unjha Life Science Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 90.15% decrease in profit. The company's net worth dipped by a decrease of 1.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unjha Life Science?
In 2021, Unjha Life Science had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Unjha Pharmaceuticals Private LimitedMalav Shah and Arpita Shah are mutual person
- Aura Nutraceuticals Limited
Malav Shah, Gatha Shah and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Unjha Life Science?
Unlock and access historical data on people associated with Unjha Life Science, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unjha Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unjha Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.